What's Going On With Crispr Therapeutics Stock Monday?
Portfolio Pulse from Adam Eckert
CRISPR Therapeutics AG (NASDAQ:CRSP) stock is trading higher due to momentum from the UK MHRA's conditional marketing authorization for its CRISPR/Cas9 gene-edited therapy, CASGEVY, for sickle cell disease treatment. The therapy is authorized for patients 12 and older, with an estimated 2,000 eligible patients in the UK. Analysts are generally positive on CRSP, with an average price target of $84.45. CRSP shares have risen 42% over the past week and 85% over the past month, with a 10.3% increase to $74.85 on Monday morning.
November 20, 2023 | 4:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CRISPR Therapeutics' stock is experiencing a significant rise following the UK MHRA's authorization of its gene-edited therapy for sickle cell disease, indicating strong market confidence in the company's technology and potential growth.
The positive impact on CRSP's stock price is directly related to the regulatory authorization of its gene therapy, which is a significant milestone for the company. The therapy's approval could lead to increased revenue and market share in the gene editing space, particularly for sickle cell treatment. The stock's recent performance and analyst ratings further support the potential for continued short-term growth.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100